Paul Ridker is a Lipoproteins and Cardiovascular Health physician affiliated with Brigham and Women's Hospital. OpenAlex indexes 1,379 publications with 234,595 citations (h-index 227); ClinicalTrials.gov lists 6 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Cardiovascular Disease profiles in the findmyKOL directory.
Data verified 24 Aug 2026
Overview
Updated 27 Aug 2026
Paul Ridker, MD, is affiliated with Brigham and Women's Hospital. The public record shows 1,379 publications with 234,595 citations (h-index 227), centered on Lipoproteins and Cardiovascular Health, Adipokines, Inflammation, and Metabolic Diseases, Diabetes, Cardiovascular Risks, and Lipoproteins. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 19 companies, 7 NIH-funded awards (1998–2026).
- Most recent indexed publication: 2026 · European heart journal
- Top research focus: Lipoproteins and Cardiovascular Health
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 26 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 895.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Sponsor: Kowa Research Institute, Inc.
- Cardiovascular Inflammation Reduction Trial
Sponsor: Brigham and Women's Hospital
- The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes
Sponsor: Brigham and Women's Hospital
Industry payments
Updated 27 Aug 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AGEPHA Pharma FZ LLCProgram year202510 payments$42,067openpaymentsdata.cms.gov ↗
- Novo Nordisk ASProgram year20254 payments$19,816openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20254 payments$15,186openpaymentsdata.cms.gov ↗
NIH funding
Updated 27 Aug 2026
7 NIH research awards on record, funded 1998–2026 per NIH RePORTER. The latest:
- (1/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): CCC
Brigham and Women'S Hospital
FY2026$3,566,116UH3HL176627 - (1/2) Statins to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT): CCC
Brigham and Women'S Hospital
FY2025$2,290,286UG3HL176627
Congress activity
Updated 27 Aug 2026
5 congress contributions (2011–2023) across AACR, ADA, ASCO, ASH per OpenAlex. The most recent:
- Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): Phase 3, investigator-initiated, randomized, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in hospitalized patients with immune checkpoint inhibitor associated myocarditis.
ASCO Annual Meeting
ASCO2023Co-authorPosterTrials in progress - 13-OR: Effects of Randomized Statin Therapy vs. Placebo on Plasma Branched-Chain Amino Acids (BCAAs) and Type 2 Diabetes (T2D) Risk: Secondary Analysis of the JUPITER Trial
ADA Scientific Sessions
ADA2021Co-authorOral
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- The value of low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) in guiding cardiovascular prevention.
European heart journal
Article2026 - Ziltivekimab in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the ATHENA and HERMES trials.
European journal of heart failure
Article2026 - A stitch in time: easily measured biomarkers to enhance cardiovascular risk prediction in primary prevention.
European heart journal
Article2025
Most-cited works
by citation count (OpenAlex)- 01Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseArticle9,260 citations2017
- 02Inflammation and AtherosclerosisArticle7,699 citations2002
- 03Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinArticle6,665 citations2008
- 04Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenArticle5,532 citations1997
- 05Progress and challenges in translating the biology of atherosclerosisArticle4,007 citations2011
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/paul-ridker-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
thecantos.org
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thecantos.org ↗ - ResearchGate
researchgate.net/scientific-contributions/Paul-M-Ridker-2128812519
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
thecirt.org
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thecirt.org ↗ - Other
thecantos.org/paul-ridker-md-mph---trial-chairman.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thecantos.org ↗ - Other
eas-society.org/2025/atherotalk-paul-ridker
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →eas-society.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Scott Solomon, MD
Brigham and Women's Hospital
Dennis Selkoe, MD
Brigham and Women's Hospital
Marc Pfeffer, MD
Brigham and Women's Hospital
Marc Sabatine, MD
Brigham and Women's Hospital